Welcome to our dedicated page for Bausch & Lomb SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bausch & Lomb's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bausch & Lomb's regulatory disclosures and financial reporting.
Trebbi Barbara reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Barbara Trebbi received an equity compensation award on 2026-08-12. She was granted 11,776 restricted share units (RSUs) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated. The RSUs are scheduled to vest immediately before the conclusion of the next annual meeting of shareholders and will be settled in common shares, resulting in direct ownership of 11,776 common shares after the award.
Bausch & Lomb Corp filed an initial statement of beneficial ownership for Barbara Trebbi, identifying her as a director of the company. The filing does not list any holdings or report any transactions in Bausch & Lomb securities. A power of attorney is referenced as an exhibit.
Bausch & Lomb Corp director Laurence E. Paul reported an acquisition of 11,776 Common Shares on 2026-08-12 through an annual grant of restricted share units (RSUs) for non-employee directors under the 2022 Omnibus Incentive Plan. These RSUs are scheduled to vest immediately before the next annual meeting of shareholders and will be settled in common shares upon vesting. Following this grant, Paul directly holds 11,776 common shares.
Bausch & Lomb Corp director Paul Laurence E filed an initial statement of beneficial ownership of securities as a Form 3. The filing lists him as a director and references an attached Exhibit 24 Power of Attorney, and it does not report any specific holdings or transactions.
Chersi Robert J reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Robert J. Chersi received an equity compensation award of 11,776 restricted share units (RSUs) of common shares under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. The RSUs will vest immediately before the conclusion of the next annual meeting of shareholders and are then settled in common shares. After this grant, Chersi directly holds 11,776 common shares.
Bausch & Lomb Corp disclosed that Robert J. Chersi is a reporting person in his capacity as a director. This initial ownership report lists no equity transactions or holdings details and notes an attached Power of Attorney authorizing certain filing-related actions.
Bausch & Lomb Corp director Thomas Appio filed an initial statement of beneficial ownership. The filing reports that he directly holds 27,583 Common Shares, No Par Value of Bausch & Lomb Corp as of the reported date. No new acquisitions, sales, or derivative positions are indicated.
Bausch & Lomb Corp executive Frederick Munsch, SVP, Controller and CAO, reported a sale of 52,900 Common Shares on August 10, 2026 in an open-market or private transaction at a weighted average price of $16.78 per share. The shares were sold in multiple trades between $16.73 and $16.85 per share, leaving him with 45,831 Common Shares held directly after the transaction.
Bausch + Lomb Corporation reports updates to its board leadership and committee assignments effective August 10, 2026. Thomas J. Appio has succeeded Brent Saunders as Chairman of the Board, while Mr. Saunders continues to serve as a director. The board has also appointed Laurence Paul, M.D. as Lead Independent Director.
On the same date, Robert Chersi joined the Audit and Risk Committee and the Talent and Compensation Committee. Dr. Paul joined the Nominating and Corporate Governance Committee and the Science and Technology Committee. John A. Paulson was named chair of the Nominating and Corporate Governance Committee, Eduardo Alfonso, M.D. as chair of the Science and Technology Committee, and Barbara Trebbi as chair of the Talent and Compensation Committee.
A shareholder of BLCO filed to potentially sell up to 52,900 shares of common stock through Fidelity Brokerage Services LLC, with trading on the NYSE targeted on or after 08/10/2026. The shares derive from multiple restricted stock vesting awards received from the issuer as compensation between 07/25/2023 and 05/05/2026, including individual vesting events of 16,131 shares on 03/01/2026 and 13,511 shares on 05/05/2026.